Skip to content
Peptides Codex
ENFR

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
GnRH agonist (decapeptide analog)

Triptorelin

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) and a long-acting agonist at the GnRH receptor.

By The Peptides Codex Editorial TeamIndividual review date not recorded

Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.

Length
10 aa
Class
GnRH agonist (decapeptide analog)
Function
Gonadotropin-releasing hormone receptor agonist
Context
Approved medicine for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty (prescription)

Long-acting GnRH agonist — chronic dosing downregulates pituitary receptors and suppresses sex hormones.

Also known as: Decapeptyl · GnRH agonist

Part of the Foundational & therapeutic peptides cluster

Overview

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) and a long-acting agonist at the GnRH receptor. It is an approved prescription medicine used in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. This page is educational and is not medical advice.

Source & context

Biological / chemical source: Synthetic decapeptide analog of GnRH

Primary research or clinical context: Approved medicine for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty (prescription)

Agonist paradox

A GnRH agonist first stimulates luteinizing hormone and follicle-stimulating hormone release, then, with sustained exposure, downregulates and desensitizes pituitary receptors. The net effect after the initial flare is reduced sex-hormone output, which underlies its clinical uses.

Structure

Triptorelin substitutes D-tryptophan at position 6 of the native GnRH decapeptide. This single change resists enzymatic breakdown and greatly extends activity, allowing depot formulations dosed weeks to months apart in approved products.

Structure & chemistry

Molecular identity & reference confidence

Source-supported reference

The long-form sequence and letter-only chain describe the same ten positions when pGlu, D-Trp at 6, and terminal Gly-NH2 are retained. Those modifications are essential to the parent-form reference; the letters alone do not encode them.

Molecular form
Triptorelin parent peptide (not a salt)
Species
Not established by this molecular identity audit
Termini (N / C)
Pyroglutamate / Amide

Average reference mass · Molecular identity assessment: 2026-10-05

Reference policy updated: 2026-10-05

Molecular formula
C64H82N18O13
Average reference mass
≈ 1,311.4
C-terminus
Amide
Status
Approved medicine in at least one jurisdiction (IUPHAR record)
Chemical modifications (IUPHAR record)

C-terminal glycine residue is amidated; the N-terminal residue is pyroglutamic acid and the tryptophan residue at position 6 is D-Trp

Identifiers

Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.

Clinical development snapshot

ClinicalTrials.gov lists 297 registered studies with “Triptorelin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.

Registered studies
297
Highest phase reached
Phase 4
Active in latest 100
62
Most recent update
2026-09-29
Most recently updated studies
NCTTitlePhaseStatusUpdated
NCT01492972Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate CancerPhase 3recruiting2026-09-29
NCT04557059A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive PrPhase 3active not recruiting2026-09-25
NCT06129539A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With CentPhase 3active not recruiting2026-09-22
NCT07816562Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)Phase 3recruiting2026-09-11
NCT04931342A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or RecurrPhase 2active not recruiting2026-09-10
NCT07751133Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPhase 3recruiting2026-09-04
See all on ClinicalTrials.gov →
Concentration math

Triptorelin — reconstitution calculator

Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.

Reference form: Triptorelin parent peptide (not a salt)Average reference mass: 1,311.4 Da

Syringe graduation
Solution concentration
5 mg/mL5,000 mcg/mL
mcg

Enter an amount to see the volume it corresponds to.

Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.

Open the Triptorelin calculator on its own page →

Change log

Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.

  1. Trials1 registered study added on ClinicalTrials.gov (now 297).

FAQ about Triptorelin

What is Triptorelin?+

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) and a long-acting agonist at the GnRH receptor. It is an approved prescription medicine used in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. This page is educational and is not medical advice.

What Canadian product status is recorded for Triptorelin?+

Canadian product status for Triptorelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.

What is the typical length of Triptorelin?+

Triptorelin is commonly described as approximately 10 amino acids (GnRH agonist (decapeptide analog)).

Related peptides

Substance P
Neuropeptide
Substance P is an 11-amino-acid neuropeptide of the tachykinin family involved in pain signaling and neurogenic inflammation research.
Defensin (HNP-1)
Antimicrobial
Human neutrophil peptide-1 (HNP-1) is an alpha-defensin antimicrobial peptide with a disulfide-stabilized structure important in innate immunity research.
Vasopressin
Hormone
Vasopressin (antidiuretic hormone) is a nine-residue peptide closely related to oxytocin, central to water balance physiology.
Matrixyl
Cosmetic peptide
Matrixyl is the trade name of palmitoyl pentapeptide-4 (Pal-KTTKS), a lipidated pentapeptide used in anti-wrinkle skincare. The C16 palmitoyl tail lets it self-assemble into nanotapes and stimulates collagen production in human dermal fibroblasts in a concentration-dependent way (Jones et al., Molecular Pharmaceutics 2013). It is a cosmetic ingredient, not a drug, and controlled human data on the peptide itself are scarce.

References & further reading

  1. 1.Yu et al. (2024). A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty. Adv Ther
  2. 2.Gravina et al. (2025). Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients. ESMO Open
  3. 3.Matveev et al. (2024). PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer. Asia Pac J Clin Oncol
  4. 4.Leone Roberti Maggiore et al. (2014). Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother
  5. 5.Chioma et al. (2025). Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls. Endocr Connect
  6. 6.Lahlou (2005). [Pharmacodynamics of triptorelin]. Rev Prat
  7. 7.Keating (2010). Triptorelin embonate (6-month formulation). Drugs
  8. 8.Danesh-Doust et al. (2023). Triptorelin Peptide Conjugated Alginate Coated Gold Nanoparticles as A New Contrast Media for Targeted Computed Tomography Imaging of Cancer Cells. Cell J
  9. 9.PubChem — compound summary for Triptorelin (CID 25074470)
  10. 10.Wikipedia — Triptorelin
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Triptorelin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.